^
Association details:
Biomarker:BRAF mutation
Cancer:Melanoma
Drug:Cotellic (cobimetinib) (MEK1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

Excerpt:
...- Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with vemurafenib -...
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma

Published date:
08/15/2022
Excerpt:
Combinatorial therapy involving bromosporine and cobimetinib (bromo/cobi) showed synergistic anti-tumor effects in multiple BRAFi-resistant PDX models. The bromo/cobi combination was superior in vivo to standard BRAFi/MEKi therapy in the treatment-naive BRAF-mutant setting and to MEKi alone in the setting of immunotherapy-resistant NRAS- and NF1-mutant melanoma.
DOI:
10.1073/pnas.2206824119